Nanomedicine in rheumatology: A new field in the diagnosis and therapy of rheumatic diseases
Journal Title: International Journal of Clinical Rheumatology - Year 2018, Vol 13, Issue 1
Abstract
Nanomedicine is a prolific and vastly expanding field of medicine rendering important new avenues to improve diagnosis and treatment of human maladies. However, safety of the nanomaterials and therapeutic agents must be carefully considered. In the forthcoming future, more anti-inflammatory drugs targeting cytokines will hopefully be nanodeveloped to treat, making ‘target-to-treat’ as important as the emerging ‘treat-to-target’ strategy. Nanomedicines that reduce the dosage, frequency and adverse-effects of the anti-inflammatory drugs used nowadays will possibly move to clinical practice.
Authors and Affiliations
Tamer A. Gheita, Sanaa A Kenawy
Keywords
Related Articles
- EP ID EP604302
- DOI -
- Views 58
- Downloads 0
Mobile health applications in rheumatology: Could they improve our care and research?
With>165,000 mobile health apps available on iTunes and Google Play mHealth is a rapidly growing field, which generated high expectations for the improvement of our health care. We identify two uses for mHealth in the fi...
Rheumatoid arthritis and the concept of autoimmune disease
We critically review the concept of autoimmunity in Rheumatoid Arthritis (RA). To classify a disease as autoimmune, it is necessary to demonstrate that the immune response to a self-antigen causes the observed pathology....
The effect of hydroxychloroquine on endothelial dysfunction in patients with rheumatoid arthritis: A doubleblind randomized clinical trial
Aim: The aim of this study was to evaluate the effect of hydroxychloroquine on endothelial dysfunction in rheumatoid arthritis patients by measuring soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble E-Selec...
Cardiovascular disease is associated with activity limitations in osteoarthritis patients
Background: To investigate the associations between Cardiovascular Disease (CVD) and Cardiovascular (CV) risk factors with activity limitations in patients with knee or hip Osteoarthritis (OA). Methods and Findings: Cons...
“Cellular matrix™ PRP-HA”: A new treatment option with platelet-rich plasma and hyaluronic acid for patients with osteoarthritis having had an unsatisfactory clinical response to hyaluronic acid alone: Results of a pilot, multicenter French study with long-term follow-up
Objective: To evaluate the safety and efficacy of Cellular Matrix™, a new medical device designed for one-step preparation of platelet-rich plasma in presence of hyaluronic acid, for the management of tibiofemoral knee o...